Upfront low ‐dose ponatinib (15 mg/day) for multi‐TKI resistant chronic myeloid leukemia

Hematological Oncology, EarlyView.

Source: Hematological Oncology - June 14, 2018 Category: Hematology Authors: AyalewTefferi Source Type: research